Program
MRNA-1018
A development code. Also written as “mRNA-1018-H5”, “mRNA-1018 for H5N8” and “mRNA-1018 for H7N9”.
Its studies are mostly in Influenza, Human, led by Moderna.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moderna | 21 open or running | phase 3since Mar 22, 2026 | Jul 25, 2023 | Jan 28, 2027phase 3 · NCT07496450 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 25, 2023First study: phase 2 study in Influenza, HumanFirst studyNCT05972174 · 1,504 enrolled · United States, United Kingdom
- Mar 22, 2026Phase 3 study in Influenza, HumanPhase 3 reachedNCT07496450 · 4,050 enrolled · United States, United Kingdom
Ahead
- Jan 28, 2027Primary completion: phase 3 study in Influenza, HumanNCT07496450
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07496450Influenza, Human · United States, United Kingdom | 3 | Active, not recruiting | Jan 28, 2027 | 4,050 |
| NCT05972174Influenza, Human · United States, United Kingdom | 2 | Completed | Jul 16, 2024 | 1,504 |
How it is read
Names in the registry
- “mRNA-1018-H5”, 1 entry
- “mRNA-1018 for H5N8”, 1 entry
- “mRNA-1018 for H7N9”, 1 entry
- “mRNA-1018 for H5 Only”, 1 entry
- “mRNA-1018 for H7 Only”, 1 entry
Codes read as this program: MRNA1018.
Conditions, from the studies’ own filings
- Influenza, Human, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.